Global Cardiopulmonary Bypass System Market Projected to Reach USD 270.9 Million by 2033 at a 3.2% of CAGR

The cardiopulmonary bypass systems market is anticipated to have consistent growth over the next ten years, increasing from an estimated USD 197.3 million in 2023 to an estimated USD 270.9 million by 2033 in terms of valuation. Over the course of the predicted period, this growth translates into a compound annual growth rate (CAGR) of 3.2%. Cardiopulmonary bypass devices sold worldwide had a net worth of about USD 173.9 million in 2018.

Heart valve replacement or repair, coronary artery bypass grafting (CABG), and other difficult cardiovascular surgeries need the use of cardiopulmonary bypass devices, which support the heart and lungs during the surgery. These systems ensure that blood is circulated throughout the body with oxygen by temporarily taking over the role of the heart and lungs.

It is projected that the need for cardiopulmonary bypass equipment would increase because to the growing expenses associated with treating major illnesses including heart diseases. However, it is expected that the unfavorable consequences of bypass surgery may hinder the adoption of these devices. On the other hand, it is anticipated that the quick advancement of technology and the rise in surgical operations would spur market growth and present market participants with fresh prospects.

Request Your Detailed Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-5855

Supporting Heart Health: Cardiopulmonary Bypass Systems Play a Vital Role

The global cardiopulmonary bypass system market is experiencing continued growth, driven by the increasing need for effective tools in cardiac surgery. Cardiopulmonary bypass systems play a critical role in open-heart surgery by temporarily taking over the functions of the heart and lungs, allowing surgeons to operate on a still heart.

Market Growth Fueled by Multiple Factors:

Several factors are contributing to the growth of the cardiopulmonary bypass system market:

• Increased Focus on Cardiac Care: Rising healthcare expenditure directed towards combating heart disease, a leading global health concern, is creating a greater demand for advanced cardiac surgical procedures.
• Technological Advancements: The market is continuously evolving with the development of innovative bypass systems. Roller pumps, for example, are gaining traction due to their affordability, ease of use, and reliable flow management.
• Expanding Surgical Needs: The growing number of lung transplant procedures, particularly en-bloc double-lung transplants, is driving the demand for cardiopulmonary bypass systems to support these complex surgeries.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-5855

Key Takeaways:

• The global cardiopulmonary bypass system market is expected to reach US$270.9 million by 2033, reflecting a rise from US$197.3 million in 2023.
• This growth is projected at a steady compound annual growth rate (CAGR) of 3.2% throughout the forecast period.
• Rising healthcare spending on cardiac procedures and advancements in technology are key drivers for market expansion.

The Cardiopulmonary Bypass System Market:

• Minnetronix Inc.
• Transonic
• MAQUET Holding B.V. & Co. KG.
• Getinge AB
• Terumo Corporation
• MicroPort Scientific Corporation
• Xenios AG
• Nipro Corporation
• Eurosets Srl
• OriGen Biomedical
• Thoratec Corporation
• Tianjin Medical
• Olympus Corporation
• Haemonetics Corporation

Some Recent Developments in the Cardiopulmonary Bypass System Market are:

• In June 2014, Sorin Group celebrated the delivery of its 10,000th heart-lung machine (S5 heart-lung machine) to Brigham and Women’s Hospital, Boston, MA, USA. Thuse achieved an exciting milestone that reflects the tremendous trust and collaborative partnership with their customers worldwide.
• In October 2021, MicroPort acquired 100% of the equity held by existing shareholders of Hemovent GmbH. Hemovent specializes in the development of ground-breaking Extracorporeal Life Support (ECLS) systems.
• In February 2022, Getinge acquired 100% of the equity interest in Talis Clinical LLC, a US-based leading innovator of High Acuity cloud-based software solutions. Talis Clinical’s offer is designed to support and document care throughout the general and cardiac perioperative care process, but also through labor and delivery episodes and critical care support, including ECMO Therapy.
• In April 2022, LivaNova initiated the targeted commercial launch of Essenz™. Patient Monitor for cardiopulmonary bypass procedures. The transformative monitoring system uses a patient-tailored approach to improve clinical efficiency and quality of patient care during cardiopulmonary bypass (CPB) procedures.
• In January 2021, Eurosets announced the full commercial release (out of the USA) of its novel ECMOlife system for Extracorporeal Life Support (ECLS). ECMOlife expands Eurosets’ portfolio to temporarily support patients in different therapeutic areas, including Extracorporeal Membrane Oxygenation (ECMO) and Mechanical Circulatory Support (MCS).

Key Segments Profiled in the Cardiopulmonary Bypass System Industry Survey Report:

By Product Type:

• Conventional
• Mini

By Modality:

• Standalone
• Portable

By End User:

• Hospitals
• Ambulatory Surgical Centers
• Cardiac Research Centers

By Region:

• North America
• Latin America
• Asia Pacific
• The Middle East and Africa
• Europe